Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Abstract HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metas...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-11-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40164-017-0091-4 |
| _version_ | 1818283093313716224 |
|---|---|
| author | Shengnan Yu Qian Liu Xinwei Han Shuang Qin Weiheng Zhao Anping Li Kongming Wu |
| author_facet | Shengnan Yu Qian Liu Xinwei Han Shuang Qin Weiheng Zhao Anping Li Kongming Wu |
| author_sort | Shengnan Yu |
| collection | DOAJ |
| description | Abstract HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results. |
| first_indexed | 2024-12-13T00:31:26Z |
| format | Article |
| id | doaj.art-ceab33b544da448890c344db46bb08d4 |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-12-13T00:31:26Z |
| publishDate | 2017-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-ceab33b544da448890c344db46bb08d42022-12-22T00:05:20ZengBMCExperimental Hematology & Oncology2162-36192017-11-016111510.1186/s40164-017-0091-4Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatmentShengnan Yu0Qian Liu1Xinwei Han2Shuang Qin3Weiheng Zhao4Anping Li5Kongming Wu6Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Interventional Radiology, First Affiliated Hospital of Zhengzhou UniversityDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Interventional Radiology, First Affiliated Hospital of Zhengzhou UniversityDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyAbstract HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results.http://link.springer.com/article/10.1186/s40164-017-0091-4HER2TrastuzumabPertuzumabT-DM1Bispecific antibodyErtumaxomab |
| spellingShingle | Shengnan Yu Qian Liu Xinwei Han Shuang Qin Weiheng Zhao Anping Li Kongming Wu Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment Experimental Hematology & Oncology HER2 Trastuzumab Pertuzumab T-DM1 Bispecific antibody Ertumaxomab |
| title | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| title_full | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| title_fullStr | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| title_full_unstemmed | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| title_short | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| title_sort | development and clinical application of anti her2 monoclonal and bispecific antibodies for cancer treatment |
| topic | HER2 Trastuzumab Pertuzumab T-DM1 Bispecific antibody Ertumaxomab |
| url | http://link.springer.com/article/10.1186/s40164-017-0091-4 |
| work_keys_str_mv | AT shengnanyu developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment AT qianliu developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment AT xinweihan developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment AT shuangqin developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment AT weihengzhao developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment AT anpingli developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment AT kongmingwu developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment |